Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07022418 · ClinicalTrials.gov registry record · Phase 2
Formoterol in Diabetes
A Phase 2 study of Diabetic Kidney Disease and Diabetic Nephropathies, sponsored by Medical University of South Carolina.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 120
- Enrollment target
- 1
- Study location
NCT07022418 is a Phase 2 study of Diabetic Kidney Disease and Diabetic Nephropathies that is actively recruiting participants, run by Medical University of South Carolina. The registered enrollment target is 120 participants, below the 5,185-participant average among 23 other Diabetic Kidney Disease trials with a reported enrollment target (98% lower). The trial reports 1 study location across 1 state.
The verdict
NCT07022418, a Phase 2 study of Diabetic Kidney Disease and Diabetic Nephropathies, is actively recruiting participants, sponsored by Medical University of South Carolina.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 120 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of the study is to evaluate if formoterol fumarate is effective in treating patients with diabetic kidney disease. Study participants will be randomly assigned to either receive formoterol fumarate (in addition to their current standard of care treatment) or standard of care treatment only. Study participants will have a 50% chance of receiving formoterol fumarate and a 50% chance of not receiving formoterol fumarate. Both groups will continue their standard of care treatment during the study. The primary goal is to gather data on feasibility and effect sizes to properly power a future clinical trial.
Conditions Studied
Interventions
- DRUG Formoterol furmarate (20 μg)
Study Locations (1)
South Carolina
- Medical University of South Carolina - Charleston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 120 participants |
| Start Date | 2025-12-01 |
| Est. Completion | 2027-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07022418
The ClinicalTrials.gov registry entry for NCT07022418 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 120 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 5,185-participant average among 23 other Diabetic Kidney Disease trials with a reported enrollment target (98% lower). The listed sponsor is Medical University of South Carolina, which has 755 total studies on file at ClinicalTrials.gov.
The record links to 2 conditions, with Diabetic Kidney Disease appearing as the primary indexed condition, and to 1 intervention - of which Formoterol furmarate (20 μg) is the first listed.
NCT07022418 reports 1 study location spanning 1 distinct geographic area - top geographies include South Carolina.
Frequently Asked Questions
What is clinical trial NCT07022418 about?
NCT07022418 is a clinical study titled "Formoterol in Diabetes". The purpose of the study is to evaluate if formoterol fumarate is effective in treating patients with diabetic kidney disease. Study participants will be randomly assigned to either receive formoterol fumarate (in addition to their current standard of care treatment) or standard of care treatment on...
What is the current status of trial NCT07022418?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 120 participants. The study started on 2025-12-01. Estimated completion is 2027-11.
What conditions does trial NCT07022418 study?
This clinical trial studies the following conditions: Diabetic Kidney Disease, Diabetic Nephropathies.
What interventions are being tested in trial NCT07022418?
The interventions under investigation include: Formoterol furmarate (20 μg) (DRUG).
Who is sponsoring clinical trial NCT07022418?
This trial is sponsored by Medical University of South Carolina, which has 755 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07022418 being conducted?
This trial has 1 study location across South Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Diabetic Kidney Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Renal Mechanism of SGLT2 Inhibition
RECRUITING · Phase 2
-
Trial of Semaglutide for Diabetic Kidney Disease in Type 1 Diabetes
RECRUITING · Phase 2
-
NAD Augmentation in Diabetes Kidney Disease
RECRUITING · Phase 2
-
Atrasentan in Patients With Proteinuric Glomerular Diseases
ACTIVE NOT RECRUITING · Phase 2
-
Evaluation of Coffee Therapy for Improvement of Renal Oxygenation
COMPLETED · Phase 2
-
A Study to Test Safety and Efficacy of Baricitinib in Participants With Diabetic Kidney Disease
COMPLETED · Phase 2
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.